<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7479EFF8-8EF7-479B-BB26-3D844EB92D8E"><gtr:id>7479EFF8-8EF7-479B-BB26-3D844EB92D8E</gtr:id><gtr:name>University of Goettingen</gtr:name><gtr:address><gtr:line1>Windausweg 2</gtr:line1><gtr:postCode>D-37073</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57336184-EF06-473F-B69C-7A2F5B259F99"><gtr:id>57336184-EF06-473F-B69C-7A2F5B259F99</gtr:id><gtr:name>Ingenious Targeting Laboratory</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7479EFF8-8EF7-479B-BB26-3D844EB92D8E"><gtr:id>7479EFF8-8EF7-479B-BB26-3D844EB92D8E</gtr:id><gtr:name>University of Goettingen</gtr:name><gtr:address><gtr:line1>Windausweg 2</gtr:line1><gtr:postCode>D-37073</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57336184-EF06-473F-B69C-7A2F5B259F99"><gtr:id>57336184-EF06-473F-B69C-7A2F5B259F99</gtr:id><gtr:name>Ingenious Targeting Laboratory</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7197FFE5-A6A9-484F-9266-9F2CB9DEA4CB"><gtr:id>7197FFE5-A6A9-484F-9266-9F2CB9DEA4CB</gtr:id><gtr:firstName>Jaya</gtr:firstName><gtr:surname>Krishnan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1102%2F4"><gtr:id>E6422C9B-C2A4-4707-AD38-32C4CEA6D82A</gtr:id><gtr:title>Epigenetic Regulation of Metabolism</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1102/4</gtr:grantReference><gtr:abstractText>The oxygen-regulated transcription factor hypoxia inducible factor 1alpha (Hif1alpha) plays a key role in the development and maintenance of the diseased state in cardiomyopathy and obesity through reprogramming of cell metabolism, growth and function. In spite of our understanding of Hif1alpha in disease, it is unclear how Hif1alpha enforces context-dependent and cell type-specific coding gene regulation during transition to the pathologic state. Recent findings from our laboratory implicate Hif1alpha-mediated transcriptional regulation of enhancer-templated non-coding RNA (eRNA) as being a critical determinant of context- and tissue-specificity of coding gene expression. This novel mode of Hif1a function plays a key role in modulating maladaptive stress-response pathways in heart disease. These studies aim to advance our understanding of oxygen signalling pathways in eRNA expression and their role in mediating key aspects of cardiac physiology, metabolism and function, and potentially laying the foundation for the development of antisense RNA-based strategies for the treatment of heart disease.</gtr:abstractText><gtr:technicalSummary>The oxygen regulated transcription factor hypoxia inducible factor 1alpha (Hif1alpha) plays a key role in development and maintenance of pathologic cardiac hypertrophy through regulation of growth and energetic pathways. Genomic enhancers are implicated in tissue- and context-dependent gene expression. To date, it remains unclear how Hif1alpha imposes context- and tissue-specific patterns of gene expression. Our recent data suggests that, in addition to its established role in the direct regulation of coding gene expression, Hif1alpha regulates enhancer-templated non-coding RNA (eRNA) expression in response to pathologic stress. eRNAs are transcribed from intergenic enhancer regions and directly contribute to the control of flanking gene expression, thereby imposing a novel regulatory layer of coding gene control. Using a combination of bioinformatics and experimental validation, we have identified Hif1alpha-dependent eRNAs that exhibit augmented expression in human and mouse cardiomyopathies. Inhibition of these eRNAs during pathologic stress induction alters flanking coding gene expression, leading to resolution of maladaptive metabolic, growth and contractile responses associated with pathologic cardiomyopathy. 
Based on these findings, our research program aims to extend these findings through systematic identification of novel Hif1alpha-regulated eRNAs in murine surgical and genetic models of cardiomyopathy by genome-wide epigenetic and transcriptomic analysis. Following which, a lentiviral short hairpin RNA (shRNA) library targeting newly identified eRNAs will be established and assessed for their capacity to inhibit in vitro pathologic-stress induced metabolic reprogramming, cardiac hypertrophy and contractile dysfunction. The functional relevance of newly identified eRNAs in mouse models of human heart disease will be studied through application of a novel adeno-associated virus 9-based long-term, inducible and cardiac-specific method of adult mouse transgenesis.
The mechanistic basis of eRNA-mediated coding gene regulation will be assessed, and complemented with correlative and associative studies of human cardiomyopathies, with the ultimate goal being the understanding of the role of the non-coding eRNA network in human heart biology and disease. 
These studies will advance the current understanding of the impact of oxygen-sensitive signalling pathways on eRNA expression and their role in mediating key aspects of cardiac physiology, metabolism and function, thereby laying the foundation for the development of clinically-relevant antisense RNA-based strategies.</gtr:technicalSummary><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1868837</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of G?ttingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Medical School</gtr:department><gtr:description>Establishment of human heart disease resource bank</gtr:description><gtr:id>72E0DACF-62CC-4B5B-882D-24F83B808D58</gtr:id><gtr:impact>Three potential publication, of which two are currently in revision.</gtr:impact><gtr:outcomeId>5464c48eb580e2.60732307-1</gtr:outcomeId><gtr:partnerContribution>Tissue collection and processing.</gtr:partnerContribution><gtr:piContribution>Analysis and classification of disease material.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Analysis of polyA processing in heart disease</gtr:description><gtr:id>F197FD86-3DD0-4F7A-9293-303CA9F24A3A</gtr:id><gtr:impact>Not at present.</gtr:impact><gtr:outcomeId>fj9z59SaTKv-1</gtr:outcomeId><gtr:partnerContribution>Genome-wide analysis.</gtr:partnerContribution><gtr:piContribution>Provided material for analysis and scientific background.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ETH Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Department of Biology</gtr:department><gtr:description>Hypoxia-induced ncRNAs in heart disease</gtr:description><gtr:id>BF0F057E-961F-4BB2-BE40-3C763DEFA747</gtr:id><gtr:impact>Developed potential therapeutic agent.</gtr:impact><gtr:outcomeId>tg9uPkpQsW8-1</gtr:outcomeId><gtr:partnerContribution>Mouse generation.</gtr:partnerContribution><gtr:piContribution>Therapeutic and biomarker development.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ingenious Targeting Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Generation of multi-transgenic mouse line</gtr:description><gtr:id>11E449DF-1B90-441E-8AFF-A030FC1619BE</gtr:id><gtr:impact>No output at present.</gtr:impact><gtr:outcomeId>oimBf7RgZNZ-1</gtr:outcomeId><gtr:partnerContribution>Transgenic mouse generation.</gtr:partnerContribution><gtr:piContribution>Concept, target, context and construct generation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Identification of a heart-specific, stress-induced non-coding RNA exhibiting a role in modulating transition to disease in heart cells.</gtr:description><gtr:grantRef>MC_UP_1102/4</gtr:grantRef><gtr:id>624F677E-3AD2-49AA-B172-50936782C27A</gtr:id><gtr:impact>None at present.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>WS2wq1Dxt8X</gtr:outcomeId><gtr:patentId>INSUFFICIENT INFORMATION</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Treatment of heart disease through modulation of hypoxia-induced eRNA activity</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Our group has identified a novel enhancer-templated non-coding RNA, eRNA-22, essential in development of hypertrophic cardiomyopathy (HCM). Mice harbouring loxP sequences flanking eRNA-22 have been generated, allowing for interrogation of eRNA-22 function in heart disease and other pathologies.</gtr:description><gtr:id>8482FD38-8D41-4C14-808D-AEB6086E3F7B</gtr:id><gtr:impact>Data generated from this mice will potentially be included in an upcoming publication.</gtr:impact><gtr:outcomeId>5464bea5a4b459.09430456</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Generation of eRNA-22 floxed mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mice harbouring loxP sequences flanking miR-27b have been generated, allowing for interrogation of miR-27b function in heart disease and other pathologies.</gtr:description><gtr:id>7B2BD0E4-7B7F-407E-8F01-783566AE5FB6</gtr:id><gtr:impact>Data generated from this mice will potentially be included in an upcoming publication.</gtr:impact><gtr:outcomeId>5464bdf4cb3111.29729129</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Generation of miR-27b floxed mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Method utilises modified adeno-associated viruses in combination with organ-specific Cre recombinase mice to achieve organ-specific and inducible mouse transgenesis.</gtr:description><gtr:id>25D8C43D-8718-4BCA-AE48-8AB166472E71</gtr:id><gtr:impact>This methodology has been used in two publications currently in revision at Nature and Nature Medicine.</gtr:impact><gtr:outcomeId>5464bfbdca70a7.27765869</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Development and optimisation of adeno-associated virus (AAV)-mediated transgenesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9EB34BE1-E04D-4CA4-895A-12BFBE503E90</gtr:id><gtr:title>The hypoxia-inducible microRNA cluster miR-199a~214 targets myocardial PPARd and impairs mitochondrial fatty acid oxidation.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd63fd222c8212eadce4cdc0f30d95c9"><gtr:id>bd63fd222c8212eadce4cdc0f30d95c9</gtr:id><gtr:otherNames>el Azzouzi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>pm_23644_24_24011070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE6AED48-07F9-469F-9D21-7AB6F7B4FE1C</gtr:id><gtr:title>VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff6d984dfc56befa0f18bfffb048e810"><gtr:id>ff6d984dfc56befa0f18bfffb048e810</gtr:id><gtr:otherNames>Thiele W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_23644_24_22797697</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1102/4</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>